Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06024746 · ClinicalTrials.gov registry record · Phase 3

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)

A Phase 3 study of Heart Failure, sponsored by Colorado Prevention Center.

Recruiting
Registry status
Phase 3
Development phase
1,500
Enrollment target
15
Study locations

NCT06024746 is a Phase 3 study of Heart Failure that is actively recruiting participants, run by Colorado Prevention Center. The registered enrollment target is 1,500 participants, below the 2,045-participant average among 397 other Heart Failure trials with a reported enrollment target (27% lower). The trial reports 15 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06024746, a Phase 3 study of Heart Failure, is actively recruiting participants, sponsored by Colorado Prevention Center.

RECRUITING
Registry status
Phase 3
Development phase
1,500 participants
Enrollment target
15
Study locations

Study Summary

Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.

Conditions Studied

Heart Failure

Interventions

  • DRUG Finerenone
  • DRUG Empagliflozin

Study Locations (15)

California

  • CON-10075 El Centro, CA Investigational Site - El Centro
  • CON-10024 Sacramento, CA Investigational Site - Sacramento

Texas

  • CON-10045 Amarillo, TX Investigational Site - Amarillo
  • CON-10015 Austin, TX Investigational Site - Austin

São Paulo

  • CON-21004 Braganca Paulista, Sao Paulo Investigational Site - Bragança Paulista
  • CON-21049 Sao Paulo, Sao Paulo Investigational Site - São Paulo

Alabama

  • CON-10004 Fairhope, AL Investigational Site - Fairhope

Georgia

  • CON-10022 Atlanta, GA Investigational Site - Atlanta

Louisiana

  • CON-10030 Baton Rouge, LA Investigational Site - Baton Rouge

Missouri

  • CON-10002 Kansas City, MO Investigative Site - Kansas City

Goiás

  • CON-21003 Goiania, Goias Investigational Site - Goiânia

Trial Details

FieldValue
Enrollment Target 1,500 participants
Start Date 2024-07-09
Est. Completion 2026-08
Phase Phase 3

Sponsor

Colorado Prevention Center

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06024746

The ClinicalTrials.gov registry entry for NCT06024746 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,045-participant average among 397 other Heart Failure trials with a reported enrollment target (27% lower). The listed sponsor is Colorado Prevention Center, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Finerenone is the first listed.

NCT06024746 reports 15 study locations spanning 12 distinct geographic areas - top geographies include California, Texas, São Paulo.

Frequently Asked Questions

What is clinical trial NCT06024746 about?

NCT06024746 is a clinical study titled "A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)". Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.

What is the current status of trial NCT06024746?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,500 participants. The study started on 2024-07-09. Estimated completion is 2026-08.

What conditions does trial NCT06024746 study?

This clinical trial studies the following conditions: Heart Failure.

What interventions are being tested in trial NCT06024746?

The interventions under investigation include: Finerenone (DRUG), Empagliflozin (DRUG).

Who is sponsoring clinical trial NCT06024746?

This trial is sponsored by Colorado Prevention Center, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06024746 being conducted?

This trial has 15 study locations across Alabama, California, Georgia, Louisiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.